Drug Trial Radar · NCT06797518
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 21, 2025
Primary completion
Nov 27, 2027
Study completion Nov 27, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease progression, including but not limited to Oxford MEST-C score.
Conditions
- Glomerulonephritis, IGA
- Immunoglobulin A Nephropathy
Interventions
IptacopanDrug
LNP023 oral capsule 200 mg b.i.d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving a reduction of minimum one order of magnitude in complement C3c mesangial deposition.Time frame: BSL, Month 9
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
UCLA Medical Center
Los Angeles, California · Recruiting
Central Florida Kidney Specialists
Orlando, Florida · Recruiting
Georgia Nephrology Research Inst
Lawrenceville, Georgia · Recruiting
CaRe Research
Chubbuck, Idaho · Recruiting
DaVita Clinical Research
Las Vegas, Nevada · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
OSU Wexner Medical Center
Columbus, Ohio · Recruiting
Prolato Clinical Research Center
Houston, Texas · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina · Recruiting
Novartis Investigative Site
Ashdod, Israel · Recruiting
Novartis Investigative Site
Hadera, Israel · Recruiting
Novartis Investigative Site
Haifa, Israel · Recruiting
Novartis Investigative Site
Nahariya, Israel · Recruiting
Novartis Investigative Site
Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting
Novartis Investigative Site
Kuala Lumpur, Selangor, Malaysia · Recruiting
Novartis Investigative Site
Riyadh, Saudi Arabia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.